For example, in NSCLC patients undergoing PD-1 or PD-1/CTLA-4 inhibitor treatment, it was detected that both TMB and candidate neoantigen level of post-progression tumor tissue were higher compared to pre-immunotherapy tumor tissue [21]. This evidence concerns the gene PDCD1 and neoplasm.